A Study to Evaluate Administration of SBT101 Gene Therapy in Adult Patients With Adrenomyeloneuropathy (AMN)
Phase 1/2 randomized, blinded dose-escalation trial of intrathecal SBT101 (AAV9-ABCD1) in adults with adrenomyeloneuropathy. Terminated early for business reasons after 9 enrolled; of 8 treated, 1 died and 5 had serious adverse events.
| Status | Terminated |
|---|---|
| Phase | Phase 1 2 |
| Primary Endpoint Result | Inconclusive |
| Enrollment | 9 |
| Start Date | 2022-11-17 |
| Primary Completion Date | 2025-06-30 |
Why Stopped
The SBT101 program for AMN was terminated for business/strategic reasons, and there were no safety concerns
Results Summary
Posted registry results cover 9 enrolled participants (4 at dose level 1, 1.0E14 vector genomes; 5 at dose level 2, 3.0E14 vector genomes) and a safety analysis set of 8 (4 per dose level). The primary outcome was safety over 2 years. All 8 had at least one treatment-emergent adverse event. A grade 3 or 4 event related to the study procedure or drug occurred in 2 of 4 at dose level 1 and 0 of 4 at dose level 2. One of 4 at dose level 1 died; serious events occurred in 3 of 4 at dose level 1 (including transverse myelitis in 1) and 2 of 4 at dose level 2 (acute adrenocortical insufficiency in 1 and deep vein thrombosis in 1). No efficacy outcome was posted and no publication is linked. The sponsor stated there were no safety concerns behind the termination.
Design Implications
Intrathecal AAV9 delivery of ABCD1 reached a dose of 3.0E14 vector genomes in adults with AMN, and the higher dose had no grade 3 or 4 related events and no deaths among 4 participants, so a dose-limiting toxicity is not shown at this level. The one transverse myelitis case, in the lower-dose cohort, shows that inflammatory spinal cord injury is a risk to monitor with intrathecal AAV, together with immunosuppression (sirolimus, tacrolimus, steroids) used here. The program stopped for business reasons before any efficacy data, so this trial neither supports nor rules out ABCD1 replacement in AMN. AMN progresses slowly, so a future trial needs a validated functional endpoint, a long follow-up and enough participants to detect a change.
Rationale
Adrenomyeloneuropathy (AMN) is the adult spinal cord form of X-linked adrenoleukodystrophy, caused by loss-of-function mutations in ABCD1, which encodes a peroxisomal transporter needed to break down very long-chain fatty acids. SBT101 is an adeno-associated virus serotype 9 (AAV9) vector carrying a functional copy of human ABCD1, given as a single intrathecal injection. AAV9 transduces cells of the spinal cord and brain after delivery into the cerebrospinal fluid, so restoring ABCD1 in the nervous system was expected to slow progression of myeloneuropathy.
Limitations
Only 9 participants were enrolled and 8 analysed, with early termination and no efficacy data posted. Safety counts are descriptive, with no comparator in the posted results although the design was randomized and blinded with an imitation procedure. Participant flow lists 5 at dose level 2 but the safety set has 4, and the registry does not explain the difference. No success criterion was stated for the safety outcome.
Registry record
This is a Phase 1/2 randomized, blinded, dose-escalation study to evaluate the safety and efficacy of intrathecal (IT) administration of SBT101, a recombinant adeno-associated virus serotype 9 (AAV9) containing a functional copy of the human adenosine triphosphate (ATP)-binding cassette transporter subfamily D member 1 (ABCD1; hABCD1) gene, in adult patients with adrenomyeloneuropathy (AMN) aged 18-65 years. Patients will receive a single dose of SBT101 via IT route (or an imitation procedure) and will be followed for safety and efficacy for 2 years. Patients receiving SBT101 will be followed for an additional 3 years (5 total) for Safety. Patients receiving an imitation procedure will be offered the opportunity to receive SBT101 after 2 years, as data indicate.
| Primary Outcomes | Adverse Events to SBT101. Any Serious TEAE. Any Serious TEAE Related to the Study Procedure or Study Drug. |
|---|---|
| Keywords | AMN, X-ALD, Adrenoleukodystrophy, X-linked Adrenoleukodystrophy, Adrenomyeloneuropathy, Myeloneuropathy, Spastic paraplegia, Hereditary Spastic Paraplegia, HSP, ALD, ABCD1, ALDP, CALD, CCALD, Brain Diseases, Metabolic, Inborn, Brain Diseases, Metabolic, Hereditary Central Nervous System Demyelinating Diseases, Leukoencephalopathies, Demyelinating Diseases, Heredodegenerative Disorders, Nervous System, Metabolism, Inborn Errors, Peroxisomal Disorders, Metabolic Diseases, Adrenal Insufficiency, Gene Therapy, AAV9, Adeno-Associated Vector |
| Maximum Age | 65 Years |
| Intervention Names | SBT101 Treatment |
| Primary Purpose | Treatment |
| Has Results | Yes |
| Countries | United States, Netherlands |
| Intervention Types | genetic |
| Study Type | Interventional |
| Healthy Volunteers | No |
| Lead Sponsor Class | Industry |
| Eligibility Sex | Male |
| Registry Last Updated | 2026-08-26 |
| Results First Posted Date | 2026-08-26 |
| Minimum Age | 18 Years |
| Modalities | gene_therapy |
| Allocation | Randomized |
| Masking | Quadruple |
| Acronym | PROPEL |
| Enrollment Type | Actual |
| Intervention Model | Parallel |
| Condition Terms | AMN, AMN Gene Mutation, X-ALD, Adrenoleukodystrophy, Paraplegia, Spastic Paraplegia, Hereditary, Brain Diseases, Metabolic, Inborn, Brain Diseases, Metabolic, Hereditary Central Nervous System Demyelinating Diseases, Leukoencephalopathies, Demyelinating Diseases, Heredodegenerative Disorders, Nervous System, Metabolism, Inborn Errors, Peroxisomal Disorders, Metabolic Diseases, Adrenal Insufficiency |
| Completion Date | 2025-08-31 |
Official Title
A Phase 1/2 Randomized, Blinded, Dose-escalation Study to Evaluate the Safety and Efficacy of Intrathecal Administration of AAV9-ABCD1 Gene Therapy (SBT101) in Adult Patients With Adrenomyeloneuropathy
Eligibility Criteria
Inclusion Criteria:
- Diagnosed with X-linked adrenoleukodystrophy (ALD), including proven mutation in the ABCD1 gene through confirmatory genetic testing, and supported by elevated circulating VLCFA levels.
- Clinical evidence of spinal cord involvement but still able to ambulate independently
Exclusion Criteria:
- Evidence of or past diagnosis of inflammatory cerebral disease.
- 15 years or more have elapsed since the initial onset of myeloneuropathy manifestations such as walking or running difficulties, bladder dysfunction, increased muscular tone, spasticity, weakness, balance problems, etc.
- Contraindications for MRI procedure and/or contrast materials.
- Contraindication to steroids, sirolimus, tacrolimus, and/or anesthetic medications.
- Unstable adrenal function (e.g., untreated or inappropriately treated adrenal insufficiency).
- History of diabetes or abnormal fasting plasma glucose (≥126 mg/dL) or hemoglobin A1C ≥6.5%.
- Patients who have received a gene therapy.
Identifiers & revision
clinicaltrials NCT05394064euclinicaltrials 2021-004410-19
